AOC3 and diabetic neuropathy: In our earlier studies on RA (Horvath et al., 2017) as well as traumatic neuropathy (Horvath et al., 2018) and diabetic neuropathy rodent models (Tékus et al., 2020), the selective AOC3 inhibitor reference compound LJP-1207 exerted similar analgesic and anti-inflammatory effects but induced severe cartilage damage (Horvath et al., 2017).